{"nctId":"NCT00970268","briefTitle":"Long-term Extension Study of the Safety, Tolerability, and Efficacy of Aclidinium Bromide in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) (LAS-MD-36)","startDateStruct":{"date":"2009-08"},"conditions":["Chronic Obstructive Pulmonary Disease"],"count":291,"armGroups":[{"label":"1","type":"EXPERIMENTAL","interventionNames":["Drug: Aclidinium bromide"]},{"label":"2","type":"EXPERIMENTAL","interventionNames":["Drug: Aclidinium bromide"]}],"interventions":[{"name":"Aclidinium bromide","otherNames":[]},{"name":"Aclidinium bromide","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Completion of a lead-in study (NCT00891462)\n\nExclusion Criteria:\n\n* Use or anticipated use of any medication prohibited in this study\n* Evidence of abnormal clinical laboratory values, vital signs, or electrocardiographic (ECG) results or the presence of abnormities in physical examination findings\n* The presence of anti-cholinergic effects (eg, dry mouth, urinary retention, narrow angle glaucoma)\n* QTcB of \\>500 msec on both the pre-dose and post-dose ECG\n* Women who are pregnant, intend to become pregnant, or are breast-feeding\n* A life expectancy of less than 1 year\n* Noncompliance with IP dosing and/or attending clinic visits during the lead-in study\n* Significant interruption of double-blind therapy during the transition from the lead-in study into the extension study.","healthyVolunteers":false,"sex":"ALL","minimumAge":"40 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline in Morning Pre-dose (Trough) Forced Expiratory Volume in One Second (FEV1)","description":"Change From Baseline (Visit 2 of lead-in Study NCT00891462, \\[LAS-MD-33\\]) to Week 52 (Week 64 From Start of NCT00891462, \\[LAS-MD-33\\]) in Morning Predose (Trough) FEV1","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.035","spread":"0.040"},{"groupId":"OG001","value":"0.069","spread":"0.028"},{"groupId":"OG002","value":"0.069","spread":"0.037"},{"groupId":"OG003","value":"0.056","spread":"0.025"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Peak FEV1","description":"Change From Baseline (Visit 2 of study NCT00891462, \\[LAS-MD-33\\])in Peak FEV1 in liters at Week 52 (Week 64 from the start of NCT00891462, \\[LAS-MD-33\\]).","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.111","spread":"0.040"},{"groupId":"OG001","value":"0.213","spread":"0.028"},{"groupId":"OG002","value":"0.222","spread":"0.038"},{"groupId":"OG003","value":"0.219","spread":"0.025"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":7,"n":44},"commonTop":["Chronic obstructive pulmonary disorder","Nasopharyngitis","Urinary tract infection","Upper respiratory tract infection","Cough"]}}}